4 Dividend-Payers From the Ultimate Stock-Pickers
These firms are both trading at a significant discount to their fair value estimates and offer a solid dividend yield.
The vast majority of our Ultimate Stock-Pickers have never been mistaken for dividend investors. That said, a handful of them-- Amana Income Investor (AMANX), Columbia Dividend Income (LBSAX), Oakmark Equity & Income (OAKBX), and Parnassus Core Equity Investor (PRBLX)--are more focused on income-producing stocks in their pursuit of investment gains. We could also argue that Warren Buffett at Berkshire Hathaway (BRK.A)/(BRK.B) has shifted his investment portfolio to be more of an income generator, with the firm's four largest stock holdings--wide-moat Wells Fargo (WFC), narrow-moat Kraft Heinz (KHC), wide-moat Coca-Cola (KO), and narrow-moat IBM (IBM)--which accounted for 59% of the insurance company's equity portfolio at the end of 2015 all yielding more than the S&P 500 TR index (at 2.2% at the end of last week).
As you may recall from our last dividend-themed article, when we screen for top dividend-paying stocks among the holdings of our Ultimate Stock-Pickers we try to home in on the highest-quality names that are currently held with conviction by our top managers. We do this by taking an initial list of more than 500 different dividend-paying stocks held by our Ultimate Stock-Pickers and then narrow it down by focusing on firms that we believe have competitive advantages, which should allow them to generate the excess returns they'll need to maintain their dividends longer term, as well as lower uncertainty regarding future cash flows. We accomplish this by screening for holdings that are widely held (by five or more of our top managers), are yielding more than the S&P 500, represent firms with wide or narrow economic moats, and have uncertainty ratings of either low or medium.
Once our filtering process is complete, we create two tables, one that reflects the top 10 dividend-yielding stocks of our Ultimate Stock-Pickers, and the other representing stocks that are paying dividends in excess of the S&P 500 that are widely held by our top managers. In our view, finding stocks that are yielding more than the benchmark index but that operate in more stable industries, where there is less uncertainty surrounding their future cash flows, should offer some downside protection for investors. Given the increased level of volatility we've seen since the start of 2016, we expect that this is at the forefront of most investors' minds. We should also note that our dividend yield calculations in each of these tables are based on regular dividends that have been declared over the past 12 months, and do not include the impact of any special (or supplemental) dividends that may have been paid out (or declared) during that time.
Top 10 Dividend-Yielding Stocks of Our Ultimate Stock-Pickers
When looking at the changes that have taken place in the list of top 10 dividend-yielding stocks of our Ultimate Stock-Pickers since we last looked at them we would note that wide-moat General Electric (GE) and Unilever (UN)/(UL), and narrow-moat National Oilwell Varco (NOV) and Qualcomm (QCOM), fell off of the list, being replaced by wide-moat Sanofi (SNY) and Novartis (NVS), and narrow-moat AbbVie (ABBV) and Cisco Systems (CSCO). While the yield environment has looked much stronger at some points since the start of 2016, by the end of last week the yield on the S&P 500 TR Index was 2.2% (slightly higher than the dividend yield of 2.1% that we noted in our last dividend-focused article).
While the sell-off in the global equity markets since the start of the year has been fairly broad, healthcare and energy stocks were hit harder than most sectors. Given the higher uncertainty ratings that are attached to many of the stocks in the energy sector, we saw relatively few names make either list of dividend-yielding stocks--with wide-moat Exxon Mobil (XOM) being the one exception. With the healthcare sector having far less uncertainty attached to it, we saw more healthcare names cropping up on our list of top 10 dividend-yielding stocks of our Ultimate Stock-Pickers, with half of the names (and the top four spots on the list) coming from the sector.
That said, there was not much conviction buying or selling of any of the names that made their way onto our list of top 10 dividend-yielding stocks, with wide-moat Procter & Gamble (PG) being the only name that stood out, having made the list of top 10 stock sales in our last Ultimate Stock-Pickers' article. Both Procter & Gamble and wide-moat Emerson Electric (EMR) have been top ideas for our analysts, with the former now trading at around 92% of our fair value estimate and the latter at 81%. We should also note that AbbVie was a new-money purchase for one of our top managers during the most recent period.
Widely Held Dividend-Paying Stocks of Our Ultimate Stock-Pickers
Looking more closely at the top 10 widely held securities that met our criteria for dividend-paying stocks, which has traditionally had very little overlap with our list of the top 10 dividend-yielding stocks, we see more diversity in the names. Only one healthcare name made this list, with the remainder consisting of three consumer defensive stocks, two each from the financial-services and technology sectors, and one from both the industrials and basic materials sectors. Procter & Gamble and Cisco were the only names that appeared on both lists.
Consumer defensive stalwarts wide-moat Procter & Gamble, PepsiCo (PEP) and Unilever once again made our list of top 10 widely held securities that met our criteria for dividend-paying stocks, as they have traditionally offered higher yields coupled with higher levels of price stability during down markets. While it certainly wasn't the smoothest of rides during January and February, all three of these stocks have recovered and are now either at or above where they started trading in 2016, which is more than can be said for many stocks. This again speaks to their consistency, which is reflected in the low uncertainty ratings for all three names, so it is not too surprising to see them remain as core holdings for many of our Ultimate Stock-Pickers.
Wide-moat Wells Fargo and US Bancorp (USB) also remained as core holdings from the financial-services sector. While bank stocks in general were routed during the first couple of months of 2016, we expect Wells Fargo and US Bancorp to remain core holdings for our top managers. Morningstar analyst Jim Sinegal, commenting on the recent sell-off in bank stocks, noted that the fears generally appear to be overblown for many banks and that defensive opportunities existed in more profitable, less volatile stocks like Wells Fargo. Both Wells Fargo and US Bancorp have Exemplary stewardship and wide moat ratings, and we believe both should be able to weather the storm. The current prices on the two stocks, with Wells Fargo trading at around 80% of our fair value estimate and US Bancorp at 76%, should provide investors with a long-term time horizon with attractive entry points into quality businesses. US Bancorp is currently a top idea from the financial-services sector.
Wide-moat United Parcel Service (UPS) was our lone remaining industrial name as General Electric fell off the list. While we can't know with absolute certainty why one of our top managers eliminates a given position (unless he or she tells us), it is likely that General Electric's departure was for positive reasons, as the solid appreciation in the company's share price during the fourth quarter of 2015 likely encouraged some managers to take profits. General Electric's shares were up some 30% from the start of September 2015 through the end of last year. While two of our Ultimate Stock-Pickers-- American Century Value (AVLIX) and Markel (MKL)--completely eliminated their stakes in the industrial firm during the fourth quarter, the shares were still held by eight of our top managers.
We also saw a change among the technology stocks represented on the list, as Qualcomm had its uncertainty rating changed to high since the last time we looked at dividend-yielding stocks, which eliminated it from our screen. Two major developments led to the increase in the uncertainty rating for Qualcomm. First, the firm has had difficulty collecting royalties from Chinese original-equipment manufacturers, despite seemingly favorable legal rulings. On top of that, an unfavorable initial report issued last year by South Korea's Case Examiner, which stated that Qualcomm's royalties should not be based on the price of the phone but on a lesser base--perhaps either the price of a cellular baseband chip or the price of all cellular components, like baseband, radio frequency, and antennas, within a phone--could significantly reduce the royalties that Qualcomm collects in that market (and might have ripple effects in other markets). Given the regulatory and legal uncertainty surrounding both of these situations, future cash flows have become less definitive.
Wide-moat Microsoft (MSFT) has, however, remained on the list of widely held dividend-paying stocks, and continues its reign as a perennial holding, both from an overall conviction point of view as well as from a dividend-yield perspective. Microsoft also saw the highest conviction buy during the period as Alleghany (Y) initiated a new position in the stock, with the shares representing more than 6% of its equity holdings at the end of 2015. Meanwhile, Cisco was our first new addition to the list of top 10 widely held dividend-paying stocks. The company has increased its dividend in each of the past six years, and while we don't view the stock as being undervalued right now--trading at 102% of our fair value estimate--three of our top managers made minor additions to their stakes in the most recent period.
The other new addition to the list was wide-moat Praxair (PX). While companies in the basic materials sector tend to have higher uncertainty ratings as a result of their exposure to demand that can be highly cyclical and pricing that can be volatile, Praxair has a medium uncertainty rating. Morningstar analyst David Silver notes that Praxair has demonstrated an ability to navigate typical cyclical downturns and currency volatility reasonably well while still keeping its competitive position intact. While there was not a lot of significant amount of buying or selling of the name by our Ultimate Stock-Pickers during the most recent period, that name continues to be held by nine of our top managers.
With valuation and safety being a top concern for investors, especially given the selloff in the global equity markets in January and February, we continue to believe that the best way for investors to protect their capital is to invest in quality businesses at attractive prices. As such, we have once again homed in on the names on both list that are trading at less than 80% of our analysts' fair value estimates, believing that there might be more value to be had in solid dividend payers offering investors a wider than average margin of safety. We've included a few of our observations below, starting with Sanofi, the cheapest holding on a price/fair value estimate basis:
Current Yield: 4.1%
Price/Fair Value: 0.74
Wide-moat Sanofi has experienced some near-term pressures for its largest blockbuster drug, a long-acting insulin product called Lantus, which currently accounts for 16% of sales. Patents for the drug expired in 2015. This, along with other headwinds facing the pharmaceutical industry, has put pressure on the stock since the second half of last year. Morningstar analyst Damien Conover believes the recent negative trends for Lantus have masked the remaining businesses at Sanofi, which he feels are poised for steady growth with strong returns on invested capital. While patent cliffs are always difficult, Conover notes that Sanofi has a robust pipeline of new drugs. The recently launched cholesterol-lowering drug Praluent could generate peak sales over EUR 2 billion, and the news for Sanofi's insulin franchise isn't all bad as a new insulin drug called Toujeo is in the early stages of a successful launch, generating EUR 98 million in sales during the most recent quarter. Conover estimates that this drug could eventually generate peak sales of over EUR 2.5 billion. The complex biologic structure of insulin products also makes them harder and more expensive to replicate, which should reduce the threat of generic competition and limit price erosion. Conover believes the backing of a strong pipeline combined with stable already marketed drugs should offset losses on Lantus and lead to modest growth of 4% annually over the next five years. He expects annual free cash flow of at least EUR 6 billion during the same time frame, supporting future distributions to shareholders through dividends and share buybacks. Conover is currently modeling average dividend-per-share growth of roughly 3% during 2016-20.
Current Yield: 3.8%
Price/Fair Value: 0.78
Pfizer also operates within the pharmaceutical industry and boasts a wide moat. Conover covers the firm and believes that investors are currently underappreciating the company's long-term potential, with the company capable of generating 9% annual earnings-per-share growth during the next five years. He expects this to be driven by the benefits provided by the Allergan (AGN) deal, as well as share repurchases. Conover believes that the purchase of wide-moat Allergan, once completed, will provide Pfizer with a rapidly growing portfolio of drugs, a lower tax rate, and a stronger moat with more diversified patent-protected drugs. With blockbuster drugs Viagra and Lyrica both coming off of patent protection within the next five years, current consternation on the part of investors is understandable, but, in Conover's view, overdone. He expects new drugs from Pfizer's expanded pipeline to help offset the impact of generic competition and is currently projecting a healthier annual growth rate of 6% over the next decade as cost-cutting plans and share repurchases take shape. Over the long run, Conover believes that a more diversified lineup of drugs should reduce the volatility of earnings, keeping the firm's uncertainty at low levels. He also notes that Pfizer remains committed to its dividend and aims to maintain a payout ratio around 50%, which, in his view, could even increase over the next several years.
Current Yield: 3.8%
Price/Fair Value: 0.79
To round out our review of the healthcare-related names that drew our attention, we now turn to wide-moat Novartis. Conover believes that the firm's moat has been built on patents, economies of scale, and a powerful distribution network. He notes that Novartis derives its primary strengths from a diversified operating platform that includes branded pharmaceuticals, generics, eye-care products, and consumer products. Although the majority of its competitors focus solely on the high-margin branded pharmaceutical segment, Novartis runs several complementary operations, which reduces overall volatility and creates cross-segment synergies. Similar to Sanofi, Novartis has a blockbuster drug that accounts for a large percentage of overall sales and that recently came off of patent protection. In Novartis' case, it is the cardiovascular drug Diovan, which accounts for roughly 10% of the company's overall sales. Novartis also has another major product, the cancer drug Gleevec, coming off of patent protection in 2016. While patent losses over the next three years will affect more than 10% of the company's total sales, Conover believes that Novartis' strong pipeline combined with stable currently marketed drugs should lead to modest growth of 2% annually over the same time frame. He expects more than a billion dollars in peak annual sales from a new cardiovascular drug, Entresto, and a new psoriasis drug, Cosentyx. These should offset Novartis' patent losses, allowing the firm to continue to invest in research and development and set up a stable lineup of next-generation drugs. Conover notes that entrenched ophthalmology and generic drug franchises create an additional layer of competitive advantage and further insulate future cash flows. This highlights the benefit of having multiple and diversified operating segments that can provide more stability and consistency than a branded-only pharmaceutical firm. Conover believes that Novartis possesses ample financial resources and that the firm's ongoing free cash flow (of about $11 billion in the 12 months ended in September) contributes to a fairly flexible financial position. He feels that the firm should have no problem covering its current dividend, which is likely to increase 4% on average in each of the next five years.
US Bancorp (USB)
Current Yield: 2.5%
Price/Fair Value: 0.76
Wide-moat US Bancorp remains a top pick in the financial-services sector, trading at a nearly 25% discount to our $52 per share fair value estimate. While Morningstar analyst Dan Werner continues to believe that US Bancorp is one of the highest-quality banks we cover, the shares have been pressured much as the rest of the banking sector since the start of the year. Werner believes that several factors should continue to work in US Bancorp's favor. First is the discipline of the bank's loan underwriting. Werner notes that during the 2008-09 financial crisis US Bancorp did not incur the same level of losses from the severe credit charge-offs as other institutions. With its well-diversified mix of loans and sound underwriting practices, net charge-offs peaked at just over 2% of loans during the crisis. Second, the bank has built an imposing slate of fee-based businesses from credit cards to wealth management and payments processing, which now account for around half of the firm's total annual revenue. US Bancorp's payments processing business, which carries payments between consumers and merchants, is particularly lucrative, helping the bank produce an exceptionally low efficiency ratio--which is typically in the low 50% range, but has been pushed up some by the historically low interest-rate environment. US Bancorp also has a lower-cost deposit base compared with the aggregate of banks insured by the FDIC. And the firm has a balance sheet that is asset-sensitive, such that any rise in interest rates should lead to net interest margin expansion, lifting both earnings and returns. Werner notes that dividends have been limited in recent years by regulators to about 30%-35% of net income, and he expects that the regulators will continue to limit large U.S. banks' dividend payouts from net income following their annual reviews. That said, dividends should continue to increase as US Bancorp demonstrates its ability to generate excess capital. Werner notes that the company aims to return 60%-80% of net income back to shareholders in the form of dividends or share repurchases.
If you're interested in receiving e-mail alerts about upcoming articles from The Ultimate Stock-Pickers Team, please sign up here.
Disclosure: Eric Compton owns no shares of any of the securities mentioned above. It should also be noted that Morningstar's Institutional Equity Research Service offers research and analyst access to institutional asset managers. Through this service, Morningstar may have a business relationship with fund companies discussed in this report. Our business relationships in no way influence the funds or stocks discussed here.
The Morningstar Ultimate Stock-Pickers Team does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.